-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
COVID-19 + NanoFlu combination investigational vaccine
Therapeutic area | Infectious disease | Status | Technology |
---|---|---|---|
Respiratory diseases | COVID-19 + seasonal influenza | Phase 1/2 | Matrix-M™ adjuvant |
Therapeutic area
Respiratory diseases
Infectious disease
COVID-19 + seasonal influenza
Status
Phase 1/2
Technology
Matrix-M™ adjuvant
About the candidate
The Novavax COVID-NanoFlu combination investigational vaccine uses the full-length, stabilized recombinant spike (rS) protein of the SARS-CoV-2 virus, and 4 wild-type recombinant Hemagglutinin (rHA) proteins from the influenza virus, as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.
Why it matters
Combination vaccines reduce the number of shots required to protect against multiple diseases. Simplifying immunizations into fewer shots may make it more likely that people get recommended vaccinations on time, reducing delays in protection.1,2 As both influenza and SARS-CoV-2 continue to circulate and evolve, combining these vaccines into a single shot could offer protection against both diseases. We believe that COVID-19 may become endemic and therefore may require seasonal vaccination, similar to the influenza vaccine.
- US CDC. Available at: https://www.cdc.gov/vaccines/parents/schedules/combination-vaccines.html [Accessed 27 Aug 2021].
- Skibinski D, et al. Glob Infect Dis. 2011;3(1):63–72. Available at: https://pubmed.ncbi.nlm.nih.gov/21572611/ [Accessed 4 Jan 2022].